Stocks
Mirati Therapeutics, Inc.MRTX
NASDAQHealthcareBiotechnology$58.70-0.17%
Price as of · delayed, not real-time
Focused on developing targeted oncology therapies, this biopharmaceutical company specializes in precision medicines for cancer treatment. Investors track Mirati Therapeutics for its pipeline of KRAS inhibitors, including investigational drugs for lung and colorectal cancers.
Market Cap: $4.1B52W Range: $27.30 – $64.41
Congressional Interest in Mirati Therapeutics, Inc. (MRTX)
2 members of Congress have disclosed 3 trades in Mirati Therapeutics, Inc. (MRTX), a Healthcare company. The buy/sell breakdown shows 2 purchases versus 1 sale, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
3
Unique Politicians
2
Buys
2
Sells
1
Who in Congress Is Trading MRTX?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2023-04-10 | Daniel Goldman | sell | $1K – $15K |
| 2023-03-06 | Daniel Goldman | buy | $1K – $15K |
| 2021-12-06 | Rohit Khanna | buy | $1K – $15K |